<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257464</url>
  </required_header>
  <id_info>
    <org_study_id>H08-02131</org_study_id>
    <nct_id>NCT01257464</nct_id>
  </id_info>
  <brief_title>Sitagliptin in Cystic Fibrosis-Related Diabetes</brief_title>
  <official_title>The Effects of the DPPIV Inhibitor Sitagliptin in Cystic Fibrosis-related Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the dipeptidyl peptidase IV (DPPIV)
      inhibitor sitagliptin is effective in the treatment of cystic fibrosis-related diabetes
      (CFRD). We hypothesize that sitagliptin will improve meal-stimulated insulin secretion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, no clinical trials have been conducted using the DPPIV inhibitor sitagliptin in
      cystic fibrosis-related diabetes. Cystic fibrosis-related diabetes is characterized initially
      by post-prandial hyperglycemia, with normal fasting sugars. As the disease progresses,
      fasting hyperglycemia develops. As sitagliptin augments post-prandial insulin release, while
      avoiding fasting hypoglycemia, it may be an alternative therapy for cystic fibrosis-related
      diabetes in individuals who do not yet require basal insulin therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin release</measure>
    <time_frame>180 minutes (during clamp)</time_frame>
    <description>The study protocol is a iv-oral hyperglycemic glucose clamp. We will assess insulin release during the clamp, comparing placebo to sitagliptin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incretin Response</measure>
    <time_frame>180 minutes (during clamp)</time_frame>
    <description>We will assess incretin release [glucoagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide(GIP)] during the glucose clamp.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100mg po one dose</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia, MK-0431, Dipeptidyl peptidase IV inhibitor (DPP-4 inhibitor)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill po one dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 years of age or older

          -  Cystic fibrosis-related diabetes with or without fasting hyperglycemia either
             untreated or using only pre-prandial repaglinide or pre-prandial bolus insulin therapy

        Exclusion Criteria:

          -  Age under 19 years

          -  Use of basal insulin therapy

          -  Creatinine Clearance &lt; 50 mL/min

          -  Active cystic fibrosis exacerbation

          -  Pregnancy

          -  Women of child-bearing age not using effective contraception

          -  Current or prior use of DPPIV inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graydon Meneilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of British Columbia Gerontology &amp; Diabetes Reserach Centre (ViTALITY)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CFRD</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>cystic fibrosis-related diabetes</keyword>
  <keyword>incretins</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>GIP</keyword>
  <keyword>GLP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

